LINTEX
920106
LINGOOD
833284
NTGEC
870436
4
CG MED EQUIP.
838810
5
Jiayu Holding
300117
US Stock MarketDetailed Quotes
ABCL AbCellera Biologics
- 2.585
- -0.335-11.47%
Close Feb 28 16:00 ET
- 2.600
- +0.015+0.58%
Post 19:58 ET
770.30MMarket Cap-4.70P/E (TTM)
2.720High2.310Low9.93MVolume2.720Open2.920Pre Close24.97MTurnover4.88%Turnover RatioLossP/E (Static)297.99MShares5.12552wk High0.73P/B525.35MFloat Cap2.31052wk Low--Dividend TTM203.23MShs Float71.910Historical High--Div YieldTTM14.04%Amplitude2.310Historical Low2.515Avg Price1Lot Size
AbCellera Biologics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -147.41%-108.56M | 59.21%-8M | -27,147.17%-28.88M | -250.56%-29.97M | 5.34%-41.71M | -115.82%-43.88M | -163.44%-19.61M | 99.92%-106K | -92.71%19.9M | -143.97%-44.06M |
| Net income from continuing operations | -11.24%-162.86M | 27.44%-34.21M | -78.63%-51.11M | -20.97%-36.93M | -1.25%-40.61M | -192.35%-146.4M | -57.73%-47.15M | -207.46%-28.61M | -349.93%-30.53M | -123.79%-40.11M |
| Depreciation and amortization | 213.97%97M | 52.60%13.9M | 416.87%38.3M | 424.21%38.04M | -4.97%6.77M | -6.67%30.89M | -40.70%9.11M | 10.12%7.41M | 20.11%7.26M | 43.17%7.12M |
| Other non cash items | -1,360.56%-84.44M | ---35.71M | ---9.61M | -5,034.59%-40.82M | 146.97%1.71M | -189.86%-5.78M | ---- | ---- | -370.41%-795K | -513.85%-3.63M |
| Change In working capital | -295.41%-25.84M | 957.56%14.9M | -180.04%-5.73M | -129.14%-8.04M | -17.75%-26.98M | -55.66%13.23M | -95.14%1.41M | 104.08%7.16M | -89.45%27.57M | 73.05%-22.91M |
| -Change in receivables | -104.91%-75.12M | -99.86%-20.86M | -76.79%-19.82M | 50.73%-15.86M | -208.16%-18.58M | -134.44%-36.66M | -115.78%-10.44M | 81.10%-11.21M | -111.65%-32.18M | 109.72%17.18M |
| -Change in payables and accrued expense | 170.41%10.64M | 159.67%15.33M | -79.46%1.39M | -94.86%1.98M | 76.74%-8.06M | -621.30%-15.1M | -166.41%-25.68M | 105.69%6.78M | 353.71%38.45M | -137.02%-34.65M |
| -Change in other current assets | -33.70%5.95M | 6.11%4.95M | -72.89%2.48M | 73.33%2.13M | 40.54%-3.61M | 753.09%8.98M | 3,228.19%4.66M | 214.18%9.15M | -64.01%1.23M | 19.77%-6.06M |
| -Change in other working capital | -41.64%32.69M | -52.87%15.49M | 318.42%10.22M | -81.50%3.71M | 425.97%3.26M | 176.55%56.01M | 143.42%32.87M | 2,141.28%2.44M | 728.16%20.08M | -88.97%620K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -147.41%-108.56M | 59.21%-8M | -27,147.17%-28.88M | -250.56%-29.97M | 5.34%-41.71M | -115.82%-43.88M | -163.44%-19.61M | 99.92%-106K | -92.71%19.9M | -143.97%-44.06M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 154.91%121.41M | 246.79%35.7M | 128.92%3.7M | 251.49%52.1M | 119.99%29.91M | 37.30%-221.11M | -42.55%-24.32M | 95.47%-12.79M | -26.45%-34.39M | -467.32%-149.61M |
| Net PPE purchase and sale | -1.88%-78.4M | -8.31%-15.63M | 8.93%-18.52M | 26.07%-20.11M | -61.11%-24.14M | -8.90%-76.95M | -17.04%-14.43M | -62.48%-20.33M | 13.16%-27.2M | -3.37%-14.98M |
| Net intangibles purchase and sale | --0 | ---- | ---- | ---- | ---- | 72.00%-560K | ---- | ---- | ---- | ---- |
| Net business purchase and sale | -43.36%-19.63M | 51.96%-1.67M | -101.52%-7.14M | -122.91%-4.91M | -32.18%-5.91M | 46.69%-13.69M | 41.17%-3.48M | 13.13%-3.54M | 70.05%-2.2M | 46.38%-4.47M |
| Net investment purchase and sale | 218.36%183.72M | 387.69%46.45M | 431.15%19.95M | 746.36%64.54M | 139.74%52.79M | 42.66%-155.22M | -1,294.13%-16.14M | 101.39%3.76M | -266.92%-9.99M | -2,064.72%-132.85M |
| Net other investing changes | 41.08%35.71M | -36.26%6.56M | 28.24%9.4M | 151.64%12.58M | 166.17%7.17M | 54.02%25.31M | 340.79%10.29M | 22.13%7.33M | -9.12%5M | 3.74%2.69M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 154.91%121.41M | 246.79%35.7M | 128.92%3.7M | 251.49%52.1M | 119.99%29.91M | 37.30%-221.11M | -42.55%-24.32M | 95.47%-12.79M | -26.45%-34.39M | -467.32%-149.61M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 23.30%12.77M | 10.01%4.14M | -52.56%3.15M | 532.70%2.65M | 718.12%2.83M | 736.12%10.36M | 978.80%3.77M | 34,994.74%6.63M | -64.28%419K | 85.37%-458K |
| Proceeds from stock option exercised by employees | ---- | ---- | -11.33%227K | 38.02%461K | 82.04%892K | ---- | ---- | --256K | --334K | --490K |
| Net other financing activities | 23.30%12.77M | 18.10%5.72M | -54.22%2.92M | 2,476.47%2.19M | 304.54%1.94M | 736.12%10.36M | 75.86%4.85M | 2,649.60%6.37M | -90.95%85K | 81.31%-948K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 23.30%12.77M | 10.01%4.14M | -52.56%3.15M | 532.70%2.65M | 718.12%2.83M | 736.12%10.36M | 978.80%3.77M | 34,994.74%6.63M | -64.28%419K | 85.37%-458K |
| Net cash flow | ||||||||||
| Beginning cash position | -61.27%160.61M | -22.92%153.93M | -15.18%175.6M | -31.52%150.86M | -61.27%160.61M | -17.26%414.65M | -50.08%199.71M | -74.67%207.04M | -61.46%220.31M | -17.26%414.65M |
| Current changes in cash | 110.06%25.62M | 179.28%31.85M | -251.95%-22.04M | 276.17%24.78M | 95.38%-8.97M | -231.15%-254.63M | -382.92%-40.17M | 98.47%-6.26M | -105.70%-14.07M | -374.52%-194.13M |
| Effect of exchange rate changes | -544.31%-2.62M | -302.25%-2.16M | 134.52%367K | -105.40%-43K | -266.67%-781K | 106.14%589K | 193.41%1.07M | 87.57%-1.06M | 166.03%797K | -4.41%-213K |
| End cash Position | 14.32%183.62M | 14.32%183.62M | -22.92%153.93M | -15.18%175.6M | -31.52%150.86M | -61.27%160.61M | -61.27%160.61M | -50.08%199.71M | -74.67%207.04M | -61.46%220.31M |
| Free cash flow | -54.02%-186.95M | 31.71%-23.63M | -131.92%-47.4M | -586.16%-50.08M | -11.52%-65.85M | -159.30%-121.38M | -286.21%-34.6M | 85.54%-20.44M | -103.02%-7.3M | -168.88%-59.05M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Trending Stocks
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call